Surgery Treatment of Glioblastoma Multiforme to Register a Double-digit Growth in next ten years, Fact.MR
March 17, 2022 11:45 ET
|
FACT.MR
ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- The Glioblastoma Multiforme Treatment Market revenues were estimated at US$ 2.6 Bn in 2021 and is anticipated to grow at a CAGR of 10.1% from...
Global Avastin (Bevacizumab) Biosimilars Market Research Report 2021: Detailed Review of the Pipeline and Affiliated Developer Landscape
October 20, 2021 05:03 ET
|
Research and Markets
Dublin, Oct. 20, 2021 (GLOBE NEWSWIRE) -- The "Avastin (Bevacizumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars,...
Global $6.85 Bn Colorectal Cancer Drugs Markets, 2015-2020, 2020-2025F, 2030F
July 09, 2021 04:58 ET
|
Research and Markets
Dublin, July 09, 2021 (GLOBE NEWSWIRE) -- The "Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering....
Global Cervical Cancer Market Landscape Report 2021: AstraZeneca Leads Industry Sponsors & Roche has the Highest Number of Completed Clinical Trials
June 15, 2021 05:08 ET
|
Research and Markets
Dublin, June 15, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Cervical Cancer" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Cervical Cancer...
China Bevacizumab Markets, 2016-2020 & 2021-2025
April 19, 2021 08:23 ET
|
Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on the Chinese Bevacizumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The sales of Bevacizumab...
Bevacizumab Biosimilar Market Sales Size Clinical Trials Forecast 2025
December 08, 2020 03:28 ET
|
KuicK Research
DELHI, India, Dec. 08, 2020 (GLOBE NEWSWIRE) -- "Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025" Report Highlights: Bevacizumab Market Opportunity:...
Global Cervical Cancer Market Report 2020: Insight, Epidemiology and Market Forecast 2017-2030 - Unmet Needs, Marketed Therapies, Emerging Therapies, Treatment and Management
December 08, 2020 03:18 ET
|
Research and Markets
Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "Cervical Cancer - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This...
Global Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast 20202030
October 09, 2020 04:24 ET
|
Research and Markets
Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been...
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer
September 10, 2020 07:45 ET
|
HalioDx
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer Marseille, France, September...
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data
June 03, 2016 16:02 ET
|
VBL Therapeutics
VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...